First reported double drug–drug interaction in a cancer renal patient under everolimus treatment: therapeutic drug monitoring and review of literature

Everolimus is an inhibitor of mammalian target of rapamycin (mTOR) used in both transplantation and cancer treatment (breast, renal and neuroendocrine). In transplantation, therapeutic drug monitoring (TDM) is recommended due to the potential drug–drug interactions with chronic medications, which ca...

Descripción completa

Detalles Bibliográficos
Autores principales: Fort-Casamartina, Eduard, Muñoz-Sanchez, Carme, Rigo-Bonnin, Raul Francisco, del Valle-Celiz, Pamela Maria, Gonzalo-Diego, Núria, Otero-Torres, Sara, Bleda-Perez, Carmen, Prats-Jimenez, Judith, Fontanals-Martínez, Sandra
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2023
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10308769/
https://www.ncbi.nlm.nih.gov/pubmed/37381038
http://dx.doi.org/10.1186/s40001-023-01172-w

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10308769/
https://www.ncbi.nlm.nih.gov/pubmed/37381038
http://dx.doi.org/10.1186/s40001-023-01172-w

Ejemplares similares